Find Clinical Trials

Inclusion Criteria: * Age 10- 21 years * Diagnosis of T2D based on clinical diagnosis or ICD 9 and 10 codes * Duration of T2D ≥ 3 months * HbA1C ≥ 7% which is the target HbA1C recommended by the American Diabetes Association * Stable medication regimen (No medication changes and no change in basal insulin dose by more than 20% in the 2 weeks prior to enrollment) * Ability to wear CGM for a total of 6 weeks while in the study. * English or Spanish speakers. * Willing to abide by recommendations and study procedures. * Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF. Exclusion Criteria: * Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, ZnT8). * Plan for undergoing bariatric surgery during the study period * Anticipated use of systemic glucocorticoids during the study period * Unable to stop taking more than 500mg/day of Vitamin C during the study period as this may affect the sensor readings. * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data. * Presence of a condition or abnormality that in the opinion of the Investigator would cause repeated hospitalizations or significant changes in medications.

Inclusion Criteria: * Age greater than or equal to 30 * Diagnosis of hypertension * One or more of the following: * Dtrial fibrillation * Diabetes * Chronic kidney disease (stage 2+) * Obesity (class 2+) * Obstructive sleep apnea * Coronary artery disease * Hyperlipidemia * Carotid stenosis (greater than or equal to 50%) * Congestive heart failure Exclusion Criteria: * History of stroke or TIA * Inability to consent or understand study * Residence in long-term acute care facility * Inability to ambulate independently * Non-English speaking * No internet access * Not residing in Virginia * Pregnancy or suspected pregnancy

Inclusion Criteria: * The target population includes all students enrolled in the third year at the Higher Institute of Nursing Sciences (ISSIS) and the Higher School of Health Sciences and Techniques (ESSTSS) for the 2025-2026 academic year. * Own a smartphone, tablet, or computer. * Have internet access. * Have an email address. * Be willing to be randomized. * Have given informed consent to participate in the study. * Be available and committed to completing the entire online intervention program and participating in all evaluations. Exclusion Criteria: * Current enrollment in another stress management program; * History of chronic psychiatric illness; * Current use of anxiolytic or psychotropic medication.

Inclusion Criteria: * Laparoscopic gyneco-oncological surgeries * Female patients aged 18-65 years * ASA physical status classification I-II-III patients Exclusion Criteria: * Patients with diabetic retinopathy * Patients with glaucoma * Patients with cerebrovascular disease * Pregnant women * Patients with known allergy to anaesthetic agents * Morbidly obese patients with BMI \> 40

Inclusion Criteria: i. Age ≥ 18 years. ii. Healthy Control Group: No diagnosis of glaucoma or ocular hypertension. iii. Glaucoma, Newly Diagnosed Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; antiglaucoma medication usage for less than 3 months. iv. Glaucoma, Long-term Medication Group: Diagnosed with angle-closure glaucoma, open-angle glaucoma, or ocular hypertension; continuous use of intraocular pressure-lowering medications for more than 1 year. v. Glaucoma, Unilateral Group: Diagnosed with unilateral glaucoma or ocular hypertension; only one eye receiving intraocular pressure-lowering treatment. Exclusion Criteria: i. History of severe ocular trauma, chemical burns, corneal ulcers, Stevens-Johnson syndrome with ocular involvement, or ocular graft-versus-host disease. ii. History of corneal surgery, conjunctival surgery, trabeculectomy, or glaucoma drainage device implantation. iii. Presence of ocular surface irregularity or limbal dysfunction due to conditions other than glaucoma or dry eye disease.

Inclusion Criteria Age ≥60 years Resident of Qujiang District Diagnosed with chronic CVD (hypertension, coronary artery disease, heart failure, atrial fibrillation, or others) Able and willing to provide informed consent Exclusion Criteria Severe cognitive impairment or inability to provide consent Life expectancy \<1 year due to non-cardiovascular disease Participation refusal

Inclusion Criteria: 1. Have been diagnosed with type 2 diabetes mellitus (T2DM) 2. Having received only dietary and exercise therapy and never taken any antihyperglycemic medications before screening; OR Having taken no antihyperglycemic medications within the 12 weeks before screening and, prior to that, having received only oral antihyperglycemic drugs in a regimen of no more than two concomitant agents. 3. Have a body mass index (BMI) ≥20 kilograms per meter squared (kg/m²) at screening 4. Be of stable weight (±5%) for at least 12 weeks before screening Exclusion Criteria: 1. Have type 1 diabetes mellitus 2. Presence of severe chronic diabetic complications at screening, including but not limited to: proliferative diabetic retinopathy, diabetic macular edema, and severe non-proliferative diabetic retinopathy requiring acute treatment; 3. History of diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization; 4. Occurrence of a Grade 3 hypoglycemic event within 12 months prior to screening, or ≥3 Grade 2 hypoglycemic events (venous or capillary blood glucose \<3.0 mmol/L) within 3 months prior to screening, or presence of hypoglycemia-related symptoms ; 5. History of severe trauma, severe infection, or surgery within 12 weeks prior to screening that may affect glycemic control; 6. Receipt of blood transfusion within 12 weeks prior to screening, or blood donation/loss ≥400 mL within 12 weeks prior to screening, or blood donation/loss ≥200 mL within 4 weeks prior to screening, or known hemoglobinopathy (such as thalassemia, hemolytic anemia, sickle cell anemia, etc.); 7. Any unstable or treatment-requiring endocrine disorders related to glycemic control other than type 2 diabetes mellitus (such as hyperthyroidism, acromegaly, Cushing's syndrome, etc.).

Inclusion Criteria: * Participants with T2DM for at least 6 months, treated with diet, exercise and/or metformin alone or in combination with either dipeptidyl peptidase 4 (DPP-4) inhibitor or sodium-glucose co-transporter 2 (SGLT2) at stable dose for the last 3 months prior to study entry and with a HbA1c between ≤ 6.5% and ≤ 10% * Body mass index (BMI) within the range of 27.0 to 45.0 kilogram per meter square (kg/m2) * Stable body weight for the 3 months prior to screening * Participants on lipid-lowering or antihypertensive drugs must be on stable doses for at least 3 months Exclusion Criteria: * Type 1 diabetes mellitus (DM), known latent autoimmune diabetes in adults, or people with an episode of ketoacidosis or hyperosmolar state requiring hospitalisation in 6 months prior to screening * Active proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy requiring acute treatment * Uncontrolled comorbid conditions commonly associated with diabetes (for example, hypertension, hyperlipidaemia) * Severe hypoglycaemia within 6 months prior to screening visit * Current autonomic neuropathy as evidenced by neuropathic urinary retention, resting tachycardia, orthostatic hypotension, or diabetic diarrhea * Have evidence of a significant, uncontrolled endocrine abnormality (e.g., thyrotoxicosis and adrenal crises) * Are currently taking a central nervous system stimulant (e.g., Ritalin-SR), with the exception of caffeinated beverage * Have a known allergy, hypersensitivity, or intolerance to any component of the study treatment (i.e., RO7204239 / placebo) formulation * Blood donation of more than 500 milliliters (mL) within the past 3 months or blood transfusion or severe blood loss within 3 months prior to screening

Inclusion Criteria: Primary cohort (N=90): 1. Female 2. ≥21 years of age 3. Stage I-III breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status 4. Completed surgery 5. Completed adjuvant chemotherapy, if indicated 6. Reported fatigue (One-item fatigue scale score ≥ 4) 7. Ability to read and communicate in English 8. Willing to provide informed consent for the study participation Exploratory cohort (N=10): 1. Female 2. ≥21 years of age 3. Stage IV breast cancer regardless of hormone receptor status or human epidermal growth factor receptor 2 (HER2) status 4. Completed surgery 5. Currently receiving systemic therapy (e.g. endocrine therapy, chemotherapy, targeted therapy or immunotherapy) 6. Reported fatigue (One-item fatigue scale score ≥ 4) 7. Ability to read and communicate in English 8. Willing to provide informed consent for the study participation Exclusion Criteria for both cohorts: 1. Pregnant or lactating 2. Presence of dementia or major psychiatric disease 3. Deemed medically unsuitable by medical team for low to moderate intensity exercise 4. Unable or unwilling for tele-counselling sessions 5. Uncontrolled pain or undiagnosed pain 6. Low blood counts: Hb \<8.0, Platelet \<50K, ANC \<1 7. Electrolyte imbalances: K \<3.0, Na \<130 8. Cardiovascular diseases, including but not limited to: LVEF \<35%, uncontrolled arrhythmias, severe coronary artery disease, severe valvular heart disease, uncontrolled hypertension etc. not cleared by a cardiologist 9. Active infection 10. Currently engaged in moderate to vigorous physical activity

Inclusion Criteria: * Consent to participate in the study * Men and women ≥ 60 years old * Average office systolic BP ≥130 mmHg * Self-reported ≥12 hours eating period per day of at least 5 days/week * Stable health history over the past 2 months Exclusion Criteria: * Fasting \>12 hours per day * Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake * Have lost ≥ 10 pounds in last 3 months * Unable to wake up at a regular time between 6-8 am * Perform overnight shift work more than 1day/week on average * Resting heart rate of \>120 beats per minute, systolic blood pressure \> 180 mmHg and/or diastolic blood pressure of \> 100 mmHg * Have been diagnosed with diabetes * On insulin or diabetes medication * Unstable angina, heart attack or stroke in the past 3 months * Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure * Pregnant or breastfeeding * Rheumatoid arthritis, Parkinson's disease or currently on dialysis * Current diagnosis of a major psychiatric condition that would impair study participation * Severe gastrointestinal disease, major gastrointestinal surgery, or active gallstone disease * Active treatment for cancer in the past year * Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart)

Inclusion Criteria: * Diagnosis of Major Depressive Disorder (MDD) * Age between 18 - 70 years * Referred for ECT treatment Exclusion Criteria: * A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold (sleep deprivation, abuse substance, etc.), previous head injury and the presence of metallic implants in the cephalic region (e.g., aneurysm clips, shunts, stimulators, cochlear implants, electrodes) except dental fill-ings and the presence of cardiac pacemakers, neurostimulators, surgical clips or other electronic equipment, comorbidity with some neurological disorders: increased intracranial pressure, space-occupying lesion, history of stroke or transient ischemic attack, brain aneurysm and any structural brain damage with increased risk for epilepsy detected with MRI * Patients with cognitive disturbances or dementia (Mini Mental State) \< 24 * Suicide attempt within 6 months before the start of the study or pre-sent risk of suicide per the investigator's clinical judgment

Key Inclusion Criteria: * Adults ≥18 and ≤74 years of age and experienced their first major depressive episode (MDE) prior to 50 years of age * Body Mass Index (BMI) ≤40 kg/m2 * Meets the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition Text Revised (DSM-5-TR) criteria for current major depressive disorder and is currently in an MDE, confirmed using the Mini International Neuropsychiatric Interview (MINI) * Participant's current MDE has a duration of ≥6 weeks and ≤24 months. Key Exclusion Criteria: * Participant has a primary diagnosis of a mood disorder other than MDD. * Participant has a history of any of the following: MDD with psychotic or catatonic features; MDD with mixed features; Bipolar I or II disorder; Obsessive-compulsive disorder; Schizophrenia, primary thought disorder, or other psychotic disorder. * Participant has a current diagnosis of any of the following: MDD with seasonal pattern; Depression with peripartum or perimenopausal onset; Post traumatic stress disorder; Antisocial or borderline personality disorder (or presence of clinically significant borderline personality traits); Panic disorder and/or agoraphobia; ADHD treated with a psychostimulant, diagnosed during the current MDE, or with unstable symptoms, as judged by the investigator. * Participant has a substance (excluding tobacco) or alcohol use disorder within the 12 months prior to screening. * Participant has had an active suicidal plan/intent within the 6 months prior to screening, presence of suicidal behavior in the last 2 years, or \>1 suicide attempt \> 24 years of age. * Participant has a history of non-suicidal self-harm behavior in the 12 months prior to screening. * Participant has used antidepressants or other prohibited medications (including benzodiazepines), within the 2 weeks (4 weeks for fluoxetine) or within a period less than 5 times the drug's half-life, whichever is longer, prior to randomization. * Participant has a history of non-response to ≥2 antidepressant drugs of adequate dose and duration in the current MDE as determined by the Antidepressant Treatment Response Questionnaire (ATRQ). * Participants with medical conditions that may interfere with the purpose or conduct of the study * Participant is pregnant, breastfeeding, or planning to become pregnant.

Inclusion criteria: (1) hypertensive patients at high risk of stroke screened in the National Screening and Intervention Project for High-risk Population of Stroke (2) willing to participate Cooperate and sign the informed consent form Exclusion criteria: (1) TIA and stroke patients (2) severe cognitive impairment (MMSE≤9) and (3) inability to use smartphones (4) Refusal to participate

Inclusion Criteria: 1. Male or female subjects aged 18 years or older. 2. Documented history of hypertension and currently taking two or more antihypertensive medications with uncontrolled blood pressure (defined as daytime systolic BP ≥135 mmHg and/or diastolic BP ≥85 mmHg on optimized medication therapy, as measured by baseline ABPM). 3. Clinical evidence suggestive of renal artery stenosis, and scheduled for renal angiography. 4. Willing and able to provide written informed consent prior to initiation of any study-related procedures, and willing to comply with all study requirements. 5. Renal angiography shows ≥70% to \<99% stenosis in at least one main renal artery with a reference vessel diameter of ≥4.0 mm. Exclusion Criteria: 1. Systolic BP ≥200 mmHg and/or diastolic BP ≥120 mmHg on the day of randomization. 2. Suspected non-atherosclerotic causes of RAS, such as fibromuscular dysplasia or large-vessel vasculitis. 3. Pregnant or breastfeeding women. 4. Participation in another clinical trial that, in the investigator's opinion, could interfere with this study. 5. Stroke or TIA within 3 months and known ≥70% carotid artery stenosis. 6. Major surgery, myocardial infarction, or any interventional procedure within the past 30 days. 7. Known LVEF \<30%. 8. Life expectancy ≤1 year. 9. Known allergy to contrast media or to any of the following medications: aspirin, clopidogrel. 10. History of renal transplantation. 11. Prior renal artery stenting or bypass surgery. 12. Affected kidney length \<8 cm on Doppler ultrasound. 13. Serum creatinine \>3.0 mg/dL (265.2 μmol/L) at baseline visit (measured by local laboratory). 14. Reference vessel diameter \<4 mm or \>8 mm on angiography.

Inclusion Criteria: 1. 18-65 years of age, inclusive, at the time of informed consent 2. BMI 30-34.9 kg/m2 3. Type 2 Diabetes Mellitus (T2DM; defined as HbA1c 6.5%), without previous sleeve gastrectomy, and without plan to perform a concurrent sleeve gastrectomy. 4. Agrees to refrain from any type of additional bariatric or reconstructive surgery that would affect body weight for the duration of the study 5. If a child-bearing female, subject must commit to not becoming pregnant and agree to use contraception for the duration of the study 6. Willing and able to comply with protocol requirements Exclusion Criteria: 1. Type 1 diabetes 2. Use of injectable insulin 3. Uncontrolled T2DM 4. Previous sleeve gastrectomy procedure or plan to perform a sleeve gastrectomy with the duodeno-ileal anastomosis procedure 5. Uncontrolled hypertension, dyslipidemia or sleep apnea 6. Prior intestinal, colonic or duodenal surgery, other than bariatric 7. Prior surgery, trauma, prostheses, disease or genetic expression which prevent or contra-indicate the procedure, including scarring and abnormal anatomy. 8. Refractory gastro-esophageal reflux disease (GERD) 9. Barrett's disease 10. Helicobacter pylori positive and/or active ulcer disease 11. Large hiatal hernia 12. Inflammatory bowel or colonic diverticulitis disease 13. Any anomaly precluding orogastric access by gastroscope and catheters, and manipulation techniques. 14. Implantable pacemaker or defibrillator 15. Psychiatric disorder, except well-controlled depression with medication for \>6 months 16. History of substance abuse 17. Woman who is either pregnant or breast feeding 18. Woman of childbearing potential who does not agree to use an effective method of contraception. 19. Any comorbidity or current status of subject's physiological fitness that in the surgeon's or anesthesiologist's opinion represents safety concerns that make the subject medically unfit for the procedure, including any significant congenital or acquired anomalies of the GI tract at or distal to the placement of the magnets. 20. Unhealed ulcers, bleeding lesions, tumor, or any other lesion at target magnet deployment site 21. Expected need for MR imaging within the first 2 months after the procedure 22. Any anomaly preventing/contraindicating endoscopic or laparoscopic access and procedures 23. Had surgical or interventional procedure within 30 days prior to procedure 24. Any scheduled surgical or interventional procedure planned within 30 days post- procedure 25. Any stroke/TIA within 6 months prior to consent 26. Requires chronic anticoagulation therapy (except aspirin) 27. Active infections requiring antibiotic therapy, unless resolved before undergoing the study procedure 28. Unable to comply with the follow-up schedule and assessments 29. Recent tobacco or nicotine product cessation within \< 3 months prior to informed consent 30. Known allergies to the device components or contrast media 31. Limited life expectancy due to terminal disease 32. Currently participating in another clinical research study with an investigational drug or medical device 33. A positive COVID-19 test prior to the study procedure in accordance with local COVID-19 protocol 34. Any condition that, in the investigator's opinion, may preclude completion of follow-up assessments through Day 360 (e.g., a medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, or poor compliance with treatment regimen)

Inclusion Criteria: * Aged 30 years and above * Blood pressure at baseline of more than 140 or 90 mm Hg on at least two separate visits or under antihypertensive medications * Willing to monitor their blood pressure and self-titrate medication * Possess a smartphone with internet access and WhatsApp/Viber at least biweekly * No cognitive deficit and able to communicate effectively to carry out study tasks * Not planning to change residence during the 6-month follow-up Exclusion Criteria: * Pregnant women * Patients in hypertensive crisis (BP ≥180/120 mm Hg) * Had a stroke in the past 30 days or are on dialysis * Individuals with self-reported serious advanced illness such as terminal cancer * Patients enrolled in other BP research during the same period

Inclusion Criteria: * Written informed consent from the patient. For patients under the age of 18, the consent of both parents/legal guardians is also required. * Patients who are eligible for treatment with the One Strength dose escalation scheme of NHD (D.p./D.f.) according to the specifications in the SmPC. These include children (5 to \<12 years), adolescents (≥12 to \<18 years) and adults (≥18 years) with allergic (IgE-mediated) diseases, such as allergic rhinitis, allergic conjunctivitis, allergic bronchial asthma (see section 4 of the current SmPC) * The treatment decision must precede the decision to participate in the study and must be independent. Exclusion Criteria: * Any contraindication according to section 4.3 of the current SmPC for NHD (D.p./D.f.) for the One Strength dose escalation scheme.

Inclusion Criteria: * Male diagnosed with T2DM * Age 30 - 60 years old * Height ≥155cm (To ensure proper ergonomics, comfort and safety during cycling) * HbA1C level between 6-8% * No resistance exercise for ≤ 3 months before participating in the current study. * Physical inactivity (moderate to vigorous exercise ≤60 minutes weekly based on International Physical Activity Questionnaires-Short Form (IPAQ-SF)) Exclusion Criteria: * Acute illness or any foot ulcer, diabetic ulcer, retinopathy, kidney, musculoskeletal, cardiovascular, or neurological disorder that could impair exercise performance or pose a risk to participants during exercise. * Insulin injection

Inclusion Criteria: 1. Voluntary Participation and Informed Consent: The participant voluntarily agrees to join this clinical trial, signs a written informed consent form, understands the study, and is willing to comply with all trial procedures. 2. Eligibility by Age and Gender: Female participants aged ≥18 years and ≤75 years on the day of signing the informed consent form. 3. Pathological Confirmation of Disease: Histopathologically confirmed diagnosis of T1-4N0-3M0 (except for T1N0M0) triple-negative invasive breast cancer, defined as negative for estrogen receptor (ER) and progesterone receptor (PgR) (immunohistochemistry: ER, PR \< 1%), and human epidermal growth factor receptor 2 (HER2) (immunohistochemistry HER2 "0\~1+"; or immunohistochemistry HER2 "2+" with no amplification on HER2 FISH gene testing). 4. Measurable Lesion: At least one lesion measurable according to RECIST v1.1 criteria. Participants diagnosed at an external institution agree to provide archived or freshly obtained tumor tissue samples (formalin-fixed paraffin-embedded \[FFPE\] tissue blocks or at least 25 unstained tumor tissue slides) for pathology review. 5. Planned Surgical Treatment: Participants are scheduled to undergo definitive surgical resection of breast cancer, including either breast-conserving surgery or mastectomy, along with sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND), and are planned to receive neoadjuvant chemotherapy. Exclusion Criteria: 1. Prior Anti-Cancer Treatments. 2. Received systemic anti-cancer treatment, including chemotherapy, radiotherapy, immunotherapy, targeted therapy (within 2 weeks for small molecule targeted therapies), or biological agent treatment within 4 weeks before enrollment. 3. Received palliative local treatments within 2 weeks before enrollment. 4. Received systemic non-specific immune modulatory treatments (e.g., interleukins, interferons, thymopeptides) within 2 weeks before enrollment. 5. Received traditional Chinese medicine or Chinese patent medicines with anti-cancer indications within 2 weeks before enrollment. 6. Prior PD-1/PD-L1 Treatment. 7. Previously received treatment with PD-1 inhibitors or PD-L1 inhibitors. 8. Concurrent Participation in Other Clinical Studies. 9. Currently participating in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study. 10. History of Other Malignancies: (1) Has a history of other malignant tumors within 5 years prior to enrollment or concurrently, except for cured basal cell carcinoma of the skin, cervical carcinoma in situ, and thyroid cancer. (2) Active Autoimmune Diseases: Has active autoimmune diseases that required systemic treatment (such as corticosteroids) within 2 years before enrollment, or has autoimmune diseases that the investigator judges may recur or require planned treatment.

Inclusion Criteria: Age between 18 and 75 years (inclusive), regardless of gender. ECOG performance status of 0-1. Expected survival of more than 3 months, as assessed by the investigator. Fertile participants must agree to use contraception. Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures. Adequate bone marrow and organ function. NECTIN-4 gene amplification positive. Exclusion Criteria: Unstable central nervous system tumors. Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1. A history of severe cardiovascular or cerebrovascular disease.